<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040713</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A19</org_study_id>
    <nct_id>NCT03040713</nct_id>
  </id_info>
  <brief_title>Flortaucipir PET Imaging in Subjects With FTD</brief_title>
  <official_title>18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the usefulness of 18F-AV-1451 in Positron Emission
      Tomography imaging for subjects diagnosed with Frontotemporal Dementia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-AV-1451 tracer uptake measured by regional SUVr</measure>
    <time_frame>75 minutes post dose administration</time_frame>
    <description>To estimate SUVr (Standard Uptake Value Ratio) in FTD subjects</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>FTD Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or TDP-43 pathology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-1451</intervention_name>
    <description>Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.</description>
    <arm_group_label>FTD Subjects</arm_group_label>
    <other_name>Flortaucipir F18</other_name>
    <other_name>[F-18]T807</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-45</intervention_name>
    <description>Subjects with no qualifying amyloid scan within three years will receive single IV administration of 370 MBq (10 mCi) of 18F-AV-45 prior to enrollment as a screening assessment</description>
    <arm_group_label>FTD Subjects</arm_group_label>
    <other_name>Florbetapir F18</other_name>
    <other_name>Amyvid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have provided informed consent or have a legally authorized (LAR) provide consent for
             study procedures

          -  Have had volumetric brain MRI obtained in site's companion protocol within one year of
             enrollment

          -  Can tolerate PET scan procedures

        Exclusion Criteria:

          -  Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or
             endocrine disturbances that pose potential safety risk

          -  Have history of risk factors for Torsades de Pointes (TdP) or taking medication known
             to cause QT prolongation

          -  Have history of drug or alcohol dependence within the last year

          -  Are females of childbearing potential who are not surgically sterile, not refraining
             from sexual activity, or not using reliable contraception

          -  Have history of relevant severe drug allergy or hypersensitivity

          -  Have received an investigational medication under FDA IND protocol within 30 days of
             planned imaging session

          -  Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging
             session

          -  Possess PET scan evidence of amyloid deposition

          -  Determined by the investigator to be unsuitable for this type of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avid Clinical Operations</last_name>
    <phone>215-298-0700</phone>
    <email>clinicaloperations@avidrp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Movement Disorder Center, UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-822-5786</phone>
    </contact>
    <investigator>
      <last_name>Irene Litvan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memory and Aging Center, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-353-3266</phone>
    </contact>
    <investigator>
      <last_name>Gil Rabinovici</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-648-6091</phone>
    </contact>
    <investigator>
      <last_name>Diana Kerwin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

